Table 2.

Effect of inhibition of Src-family of tyrosine kinases on the proconvulsive effects of C2-ceramide

	Dose	Onset (min)	Number of seizures	Time in ictal activity (min)	Time in spikes (min)
Dihydroceramide	2 µg	8.6 ± 0.7	8.0 ± 1.0	5.4 ± 0.5	44.0 ± 3.4
C2-Ceramide	2 µg	8.9 ± 1.4	18.0 ± 2.0**	13.4 ± 1.0**	51.1 ± 3.7
CGP076030	65 ng	8.1 ± 1.0	10.0 ± 2.0	6.3 ± 1.1	53.3 ± 7.5
CGP076030 + C2-Ceramide		8.4 ± 1.6	8.0 ± 1.0††	5.5 ± 0.4††	45.0 ± 3.3

Data are the mean ± SE (n = 7–9 mice in each experimental group). C57BL6 mice were injected intrahippocampally with C2-ceramide (2 µg/0.5 µl) or CGP076030 (65 ng/0.5 µl), or their combination before intrahippocampal kainic acid injection (7 ng/0.5 μl). **P < 0.01 versus the inactive analog dihydroceramide; ^††P < 0.01 versus C2-ceramide by two-way ANOVA followed by Tukey's test [F(DF) for each treatment group are reported in the Results section].